BIOX

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Fiscal 2026 performance was significantly impacted by ongoing litigation with specific creditors and the resulting business disruptions from these disputes. The 18% revenue decline was primarily driven by the international business and a strategic reconfiguration of the seed business model. Commercial operations in Argentina have stabilized following a successful reprofiling of local debt obligations at the start of the fourth quarter. Management prioritized a leaner operating structure, achieving a 19% reduction in SG&A for the quarter to offset gross profit declines. Underlying portfolio health is improving, with core categories like microbeaded fertilizers and adjuvants delivering higher gross profit despite top-line headwinds. A comprehensive strategic assessment led to the decision to rationalize the portfolio, as 99% of aggregated gross profit currently stems from less than 50% of catalog SKUs. Management is targeting a 40% gross margin for fiscal 2027 and beyond by focusing on high-quality revenue streams, particularly in Brazil. The company aims to reduce total SG&A to 23% of revenues by fiscal 2028 through organizational simplification and new system implementations. Future growth initiatives will prioritize value-accretive SKUs and the realignment of R&D investments with strictly defined financial objectives. Capital allocation will focus on cash generation, working capital discipline, and addressing the company's complex capital structure and liquidity position. The company will continue to pursue legal remedies regarding the New York litigation while simultaneously evaluating constructive alternatives to resolve the dispute. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Reported gross profit was negatively impacted by a $4 million nonrecurring inventory adjustment related to obsolescence following a portfolio review. Approximately $118.6 million of secured notes remain classified as short-term debt due to the ongoing acceleration dispute with noteholders. The company successfully reprofiled $28 million in bank debt and extended maturities for $46.5 million in local Argentine bonds to strengthen liquidity. The wind-down of the legacy seed business model accounted for approximately half of the 18% full-year revenue decline in continuing operations.

This article first appeared on GuruFocus. Revenue (Q4 FY2026): $55.9 million, slightly above $55.4 million in prior year. Revenue (Full Year FY2026): Declined 18% to $238 million. Crop Nutrition Revenue (Q4): Increased 36% year-over-year, driven by microbeaded fertilizer. Gross Profit (Q4): $12.7 million, down 6%, with gross margin of 22.8%. Gross Profit (Full Year): $82.9 million, down 21%, with gross margin of 34.8%. Inventory Adjustment: Approximately $4 million non-recurring obsolescence charge in Q4. Adjusted EBITDA (Q4): Positive $0.6 million, improved approximately $10 million year-over-year from negative $9.6 million. Adjusted EBITDA (Full Year): $25.5 million, down 12% from $28.9 million in FY2025. SG&A (Q4): Down 19% year-over-year. Operating Expense Improvement (Full Year): More than $20 million improvement. Total Financial Debt: $225.9 million as of June 30, roughly stable versus end of Q3. Cash and Short-Term Investments: $12.2 million. Net Financial Debt: $213.6 million. Secured Notes: $118.6 million classified as short-term at year end. Debt Reprofiling: Approximately $28 million of bank debt obligations at Rizobacter; $46.5 million aggregate principal of local bonds in Argentina. Gross Margin Target (FY2027+): Approximately 40%. SG&A Target (FY2028): Combined 23% of revenues. Warning! GuruFocus has detected 8 Warning Signs with BIOX. Is BIOX fairly valued? Test your thesis with our free DCF calculator. Release Date: September 15, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fourth-quarter revenues from continuing operations were broadly stable year-over-year at $55.9 million, with improved performance across several core product categories. Crop Nutrition segment revenues increased 36% year-over-year in Q4, driven by strong microbeaded fertilizer performance. Adjusted EBITDA improved by approximately $10 million year-over-year in Q4, turning positive at $0.6 million, as cost actions flowed through the P&L. SG&A expenses declined 19% in Q4, with reductions in both fixed and variable expenses, more than offsetting the decline in reported gross profit. The company successfully reprofiled approximately $28 million of bank debt obligations and completed a voluntary maturity extension for $46.5 million of local bonds in Argentina, strengthening its liquidity profile. Full-year revenues declined 18% to $238 million, with a consequential decline in gross profits and adjusted EBITDA. Reported gross profit for Q4 was $12.7 million, down 6%, and included approximately $4 million of non-recurring inventory obsolescence charges. Full-year reported gross profit fell 21% to $82.9 million, with gross margin declining to 34.8%. The company remains in ongoing litigation with noteholders, and $118.6 million of secured notes are classified as short-term due to an acceleration dispute. Net financial debt stood at $213.6 million as of June 30, with only $12.2 million in cash and short-term investments, highlighting a leveraged balance sheet. Q: There are no questions at this time. I will now turn the call back over to Federico Trucco for the closing remarks.A: Federico Trucco, Chief Executive Officer, Executive Director: Thank you. With this, we can end the call for today. Have a great rest of the week. ---**Note to Readers:** The Q4 2026 Bioceres Crop Solutions Corp earnings call did not include a Q&A session, as no analysts or investors submitted questions during the call. The highlights below are drawn from the prepared remarks delivered by CEO Federico Trucco and CFO Ezequiel Simmermacher, which represent the most significant and relevant information from the transcript. Q: How did Bioceres perform in fiscal year 2026, and what were the main challenges?A: Federico Trucco, Chief Executive Officer: Fiscal 2026 was a challenging year, marked by ongoing litigation with certain creditors and the business consequences from this dispute. Revenues from continuing operations declined 18%, with consequential declines in gross profit and adjusted EBITDA. The decline was most significant in the international business, while commercial operations in Argentina mostly stabilized, partly due to the successful reprofiling of local debt obligations toward the beginning of the fourth quarter. Q: What were the fourth quarter revenue and gross profit results, and what drove them?A: Ezequiel Simmermacher, Chief Financial Officer: Fourth quarter revenues were $55.9 million, slightly above the $55.4 million in the prior year. Growth came mainly from the Crop Nutrition segment, up 36% year-over-year on strong microbeaded fertilizer performance, offset by lower revenues in crop protection and seeds. Reported gross profit for the quarter was $12.7 million, down 6%, with a gross margin of 22.8%. The quarter included approximately $4 million of non-recurring inventory adjustments related to obsolete products, which masked improved profitability across several core product categories. Q: What were the full-year revenue and gross profit figures for fiscal 2026?A: Ezequiel Simmermacher, Chief Financial Officer: For the full year, revenues declined 18% to $238 million. Approximately half of that decline was associated with the seeds business reconfiguration, with most of the remaining decline in crop protection, while Crop Nutrition revenues were broadly stable. Reported gross profit was $82.9 million, down 21%, with a gross margin of 34.8%. The decline was significantly affected by the high inventory obsolescence charge and the wind-down of the seed business model. Q: How did adjusted EBITDA perform, and what drove the improvement?A: Ezequiel Simmermacher, Chief Financial Officer: Adjusted EBITDA improved by approximately $10 million year-over-year in the quarter, from negative $9.6 million to positive $0.6 million. The main driver was a reduction in the operating expense base, with SG&A down 19% in the quarter, as reductions in both fixed and variable expenses more than offset the decline in reported gross profit. For the full year, adjusted EBITDA was $25.5 million compared to $28.9 million in fiscal year 2025. Despite an 18% revenue reduction and a 21% reduction in reported gross profit, adjusted EBITDA declined by only 12%, demonstrating the magnitude of the cost actions implemented during the year. Q: What is the status of the company's balance sheet and debt obligations?A: Ezequiel Simmermacher, Chief Financial Officer: Total financial debt on June 30 was $225.9 million, roughly stable compared with the end of the third quarter. Cash and short-term investments totaled $12.2 million, resulting in net financial debt of $213.6 million. Following the acceleration note associated with the noteholders dispute, substantially all of the related secured notes, $118.6 million at year end, remain classified as short-term. The company continues to dispute the acceleration of the notes and the foreclosure process, which remains subject to ongoing legal proceedings. Outside the secured notes, the company reprofiled approximately $28 million of bank debt obligations at Rizobacter and completed a voluntary maturity extension process for local bonds in Argentina covering $46.5 million in aggregate principal amount. Q: What is the outlook and strategic roadmap for fiscal year 2027 and beyond?A: Federico Trucco, Chief Executive Officer: The company has substantially completed the nearly two-year reconfiguration of its seed business and concluded an external strategic assessment of continuing operations. The roadmap includes rationalizing the portfolio and go-to-market channels, revisiting commercial policies and strategic relationships, and realigning R&D and investments with defined financial objectives, while continuing to explore further efficiencies on the OpEx front and non-core asset monetization opportunities. For fiscal year 2027 and beyond, the company is targeting about 40% gross margins by focusing growth on higher-quality core revenue streams, particularly in Brazil, and simplifying the product portfolio to focus on the most valuable SKUs. Notably, 99% of aggregated gross profit from fiscal year 2025 resulted from less than 50% of the SKUs in the catalog. Q: What are the targets for SG&A and cost structure improvement?A: Federico Trucco, Chief Executive Officer: The company has made great progress on the SG&A front and believes it can continue to improve, targeting a combined 23% total SG&A as a percent of revenues for fiscal year 2028. This is believed achievable as the company implements new systems and simplifies its organizational arrangement in terms of processes, cost centers, and legal entities. Q: What are the company's priorities as it enters fiscal year 2027?A: Federico Trucco, Chief Executive Officer: As the company enters fiscal 2027, its focus remains on improving the performance and cash generation of the continuing business, maintaining cost and working capital discipline, and actively addressing the company's capital structure and liquidity position. The actions taken during fiscal 2026 have established a more focused operating base from which to move forward. The company continues to recognize the significance of the ongoing litigation process in New York and will continue to pursue the appropriate legal course as well as evaluate constructive alternatives where possible. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Image source: The Motley Fool. Tuesday, Sept. 15, 2026 at 8:30 a.m. ET Head of Investor Relations - Maria Paula Savanti Chief Executive Officer - Federico Trucco Chief Financial Officer - Ezequiel Simmermacher Operator: Everyone. Thank you for joining us, and welcome to the Bioceres Crop Solutions fiscal fourth quarter and full year 2026 Financial Results Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press *1 to raise your hand, To withdraw your question, press *1 again. I will now hand the conference over to Maria Paula Savanti, Head of Investor Relations. Paola, please go ahead. Maria Paula Savanti: Good morning, and thank you. Welcome, everybody, to Bioceres Crop Solutions Fourth Fiscal Quarter and Full Year 2026 Earnings Conference Call. Our prepared remarks today will be led by our Chief Executive Officer, Federico Trucco; our Chief Financial Officer, Ezequiel Simmermacher. Both of them will be available for the Q&A session following the presentation. During this call, we will be making forward looking statements. These statements are based on current expectations and assumptions. That are subject to various risks and uncertainties. I refer you to the forward looking statements section of the earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non GAAP financial measures. Reconciliations of the non GAAP measures can be found in our earnings press release. The conference call is being webcast, and the link is available at our Investor Relations website. It is now my pleasure to turn over the call to Federico. Federico Trucco: Thanks, Paola, and thank you, everyone, for joining us today. Good morning. Please turn to slide number 3 for today's highlights. Fiscal 26 was a challenging year for Bioceres. Marked by the ongoing litigation with certain of our creditors and the business consequences emanating from these disputes. Revenues from our continuing operations declined by 18%, with its consequential decline in gross profits and adjusted EBITDA. Excluding changes associated towards new seed business strategy, the decline in revenues has been most significant in our international business. But in Argentina, our commercial operations have mostly stabilized. In part because of the successful reprofiling of our local debt obligations towards the beginning of the fourth quarter. Against that backdrop, our priorities have been to focus the business on our core capabilities reduced our cost structure, and strengthen operating discipline. Fourth quarter results provide encouraging evidence of progress. Revenues from continuing operations were broadly stable year over year, with improved performance across several of our core product categories. At the same time, the cost actions implemented throughout the year resulted in a materially lower expense base. Allowing us to return to positive adjusted EBITDA in the quarter. Ezekiel will now review our financial performance for the quarter and the full year. I will then return to discuss our outlook towards the end of today's call. Ezequiel? Ezequiel Simmermacher: Thank you, Federico, and good morning, everyone. Before I begin, I want to remind everyone that unless otherwise indicated, the result I will discuss today reflects our continuing operation for all periods presented. Prior year amount have been recast to exclude Pro Farm Group and are presented on a comparable basis. With that, let's turn to Slide 4 and our revenue performance. Revenues for the fourth quarter were $55.9 million slightly above the $55.4 million the prior year. The main source of growth during this quarter came from the Crop Nutrition segment increasing by 36% year over year mainly as a result of a strong performance in microbeaded fertilizer. This increase was offset by lower revenues in crop protection and in seeds. For the full year revenues, declined 18% to $238 million approximately half of that decline was associated with the before-mentioned seed business reconfiguration. Most of the reminding decline was in crop protection, while crop nutrition revenues were broadly stable for the year. Within crop nutrition, the strong performance of microbeated fertilizer was offset by lower inoculant revenue. Moving to gross profit, let's turn to Slide 5. Reported gross profit for the quarter was $12.7 million down 6%, with gross margin of 22.8%. There are a few important factors behind those reported number. First, the quarter included approximately $4 million of nonrecurring inventory adjustment related to obsolescence following a comprehensive review. These had a meaningful impact on reported gross profit and mask improved profitability across several of our cross product categories. Crab nutrition is probably the clearest example. Gross profit increased 37% led by microbeaded fertilizer where we have both high revenues and improved margins. In crop protection, the overall decline was concentrated in third party and other products. Our adjuvants portfolio actually delivered higher gross profit and improved margins year over year. And within Seeds and Integrated Product, the remaining Seeds continue to weigh wait on reported results, but seed treatment packs delivered higher sales and approximately 40% growth in gross profit. Reported consolidated gross margin does not yet tell the full story. Beneath the headline numbers, we are seeing early signs of improvement across several of our core business, providing a strong foundation for future performance. Turning to the slide to look for the full year gross profit results. For the full year, reported gross profit was $82.9 million down 21% with gross margin of 34.8%. As with the quarterly numbers, understanding the component of that decline is important. There were some significant effects during the year. The higher inventory obsolescence charge we just discussed and the wind-down of the seed business model. Looking at the underlying product performance, Crop Protection margins were broadly stable for the year despite lower revenues. microbe-based fertilizer increased gross profit by approximately 20%. And seed and seed treatment packs also delivered higher gross profit and improved margins. The largest reported decline was in crop nutrition, particularly inoculants, where the year over year comparison was significantly affected by the inventory obsolescence charge. So while reported consolidated gross margin decline, the underlying composition of the portfolio continues to improve with a greater concentration of product that offers stronger profitability. Turning to Slide 7. Look at adjusted EBITDA. This is where the impact of the cost actions we have been implementing throughout the year becomes much more visible. Adjusted EBITDA improved by approximately $10 million year over year from negative $9.6 million to positive $600 thousand The main driver was a reduction in our operation expense base. SG&A was down 19% in the quarter. With reduction in both fixed and variable expenses and those savings more than offset the decline in reported gross profit. Other income also contributed positively during the quarter, reflecting gains from joint farming and barter arraignments. So although $600 thousand is still a modest level of EBITDA, the important point for us is that the magnitude in the year over year improvement and the fact that the cost action taken during fiscal year 2026 are now clearly flowing through the P&L. For the full year adjusted EBITDA was $25.5 million compared to the $28.9 million in fiscal year 2025. This REIT illustrates the scale of the cost reset Gross profit declined by approximately $22 million year over year, but this was substantially offset by the more than $20 million improvement in operating expense. Despite 18% reduction in revenues and the 20% reduction in reported gross profit, adjusted EBITDA declined by only 12%. We think that demonstrate the magnitude of the cost actions implemented during the year and the significantly leaner operating structure with which we are entering fiscal year 2027. Finally, turning to the balance sheet. Total financial debt on June 30 was $225.9 million broadly stable compared with the end of the third quarter. Cash and short term investment totaled $12.2 million resulting in net financial debt of $213.6 million As we have previously discussed, following the acceleration note associated with the noteholders dispute, substantially all of the related secured note, a $118.6 million at year end, remains classified as short term. The outstanding balance does not reflect any reduction in connection with the pro forma foreclosure closure. The company continues to dispute the acceleration of the note and the foreclosure process, which remains subject to legal proceedings. Outside the secured notes, we also made meaningful progress on liability management during the year that was completed through the fourth quarter. At Rizobacter, we successfully pursued the reprofiling of approximately $28 million of bank debt obligations and completed a voluntary maturity extension process for our local bond debt in Argentina covering $46.5 million in aggregate principal amount of outstanding notes. This initiative further strengthened our liquidity profile and extend our debt maturity schedule. Managing liquidity and the capital structure remains a key priority as we enter fiscal year 2027. Alongside the operating and working capital initiatives that Federico has mentioned. Operator: So let's turn to-- Thanks, Ezequiel. Federico Trucco: And please now turn to Slide 10 for a brief discussion on what to expect for the year ahead. We have now substantially completed the nearly 2-year reconfiguration of our seed business. And concluded an external strategic assessment of our continuing operations. That work has provided a clear road map for the next phase of the business. Including rationalizing our portfolio and go to market channels, revisiting some of our commercial policies and strategic relationships, and realigning our R&D and our investments with defined financial objectives. While continuing to explore further efficiencies on the OpEx front and noncore asset monetization opportunities. These actions are also beginning to translate into improved portfolio profitability. Although the benefits are not yet fully reflected in reported gross margins, as we work through the portfolio and commercial transition described before. For instance, if you now turn to the next slide, you will see that if we adjust the nonrecurring obsolescence associated to the portfolio transition, gross profit percent has already expanded from fiscal year 2025 to fiscal year 2026. For fiscal year 2027 and beyond, we are targeting about 40% gross margins. We believe that this can be achieved by focusing growth on higher quality core revenue streams particularly in Brazil, as well as simplifying the product portfolio to focus on the most valuable and value accretive SKUs. Just for reference, 99% of the aggregated gross profit from fiscal year 25 resulted from less than 50% of the SKUs in our catalog. So we see a great opportunity in this work. We have also made great progress on the SG&A front as we have already discussed during the presentation, and you can see these summarized in the next slide. Yet, we believe that we can continue to improve on this front, targeting a combined 23% total SG&A as a percent of revenues for fiscal year 2028. We believe this is achievable as we implement new systems and simplify our organizational arrangement in terms of processes, cost centers, and legal entities. As we enter fiscal 2027, our focus remains on improving the performance and cash generation of our continuing business. Maintaining cost and working capital discipline, and actively addressing the company's capital structure and liquidity position. We believe the actions taken during fiscal 2026 have established a more focused operating base from which to move forward. We continue to recognize the significance of the ongoing litigation process in New York. where we will continue to pursue the appropriate legal course as well as evaluate constructive alternatives where possible. With this, we end our prepared remarks. We can now open the call for Q&A. Operator? Operator: Thank you. We will now begin the Q&A session. Please limit yourself to 1 question and 1 follow-up. If you would like to ask a question, please press *1 to raise your hand. To withdraw your question, press 1. Again. Ask that you pick up your handset when asking a question to allow for optimal sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. There are no questions at this time. I will now turn the call back over to Federico Trucco for closing remarks. Federico Trucco: Thank you. With this, we can end the call for today. Have a great rest of the week. Operator: This concludes today's call. Thank you for attending. You may now disconnect. Before you buy stock in Bioceres Crop Solutions, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bioceres Crop Solutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $433,160!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,254!* Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of September 15, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Bioceres (BIOX) Q4 2026 Earnings Call Transcript was originally published by The Motley Fool

Total revenues were $55.9 million in 4Q26 and $238.3 million in FY26 ROSARIO, Argentina, September 14, 2026--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter ended June 30, 2026. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Presentation of Results In January 2026, the Company’s Pro Farm Group (PFG) business was subject to a foreclosure auction. For accounting purposes, PFG has been classified as discontinued operations. The Company disputes the acceleration of the relevant notes and the foreclosure process, which remain subject to ongoing legal proceedings. Accordingly, unless otherwise indicated, the financial results discussed below reflect the Company’s continuing operations for all periods presented, and prior-year amounts have been recast to exclude the PFG business. Financial & Business Highlights Revenues were $55.9 million in 4Q26, broadly stable year-over-year, as 36% growth in Crop Nutrition offset lower Crop Protection revenues and the impact of the Seeds business reconfiguration. FY26 revenues were $238.3 million, down 18%, with approximately half of the decline attributable to the now substantially completed reconfiguration of the Seeds business and the associated reduction in HB4-related activities. Gross profit was $12.7 million in 4Q26, compared to $13.6 million in 4Q25, including a $4.0 million non-recurring inventory adjustment arising from an updated assessment of inventory obsolescence. The impact of this adjustment masked improved performance across several core product categories during the quarter. For FY26, gross profit was $82.9 million, down 21%, with improved performance in several core product categories offset by lower contribution from inoculants and higher inventory obsolescence charges. SG&A expenses declined by $4.9 million in 4Q26, a 19% year over year reduction, and $22.5 million in FY26 — representing a 24% reduction versus the previous fiscal year. These reductions reflect the cumulative impact of the cost actions implemented during the year. Net loss from continuing operations improved to $31.8 million in 4Q26 from $54.4 million in 4Q25, while Adjusted EBITDA1 improved $10.1 million from negative $9.6 million to positive $0.6 million, mainly supported by the materially lower operating expense base. For FY26, net loss from continuing operations was $54.4 million compared to $49.1 million in FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million Management Review Mr. Federico Trucco, Bioceres’ Chief Executive Officer, commented: "Fiscal 2026 was a challenging year for Bioceres, marked by the ongoing litigation with certain of our creditors and the resulting business consequences, as we have discussed in our previous reports. Against that backdrop, our priorities have been to focus the business on our core capabilities, reduce our cost structure and strengthen operating discipline. Fourth-quarter results provide encouraging evidence of progress. Revenues from continuing operations were broadly stable year-over-year, with improved performance across several of our core product categories. At the same time, the cost actions implemented throughout the year resulted in a materially lower expense base, allowing us to return to positive Adjusted EBITDA. "We have now substantially completed the nearly two-year reconfiguration of our Seed business and concluded an external strategic assessment of our continuing operations. That work has provided a clear roadmap for the next phase of the business, including rationalizing our portfolio and go-to market channels, revisiting some of our commercial policies and strategic relationships and re-aligning our R&D&R investments with defined financial objectives, while continuing to explore further efficiencies on the OPEX front. "These actions are also beginning to translate into improved portfolio profitability, although the benefits are not yet fully reflected in reported gross margin as we work through the portfolio and commercial transitions described above. The performance of several of our core product categories gives us confidence in the direction of these initiatives and their potential to support stronger and more consistent profitability. "As we enter fiscal 2027, our focus remains on improving the performance and cash generation of our continuing businesses, maintaining cost and working-capital discipline, and actively addressing the Company’s capital structure and liquidity position. We believe the actions taken during fiscal 2026 have established a more focused operating base from which to move forward." Key Financial Metrics Table 1: 4Q26 & FY26 Key Financial Metrics 4Q26 & FY26 Summary: Revenues from continuing operations were $55.9 million in 4Q26, broadly unchanged from the prior-year quarter, as growth in Crop Nutrition offset lower Crop Protection revenues and the impact of the Seeds business reconfiguration. Gross profit was $12.7 million compared to $13.6 million in 4Q25, as improved performance across several core product categories was offset by higher inventory obsolescence charges. SG&A expenses declined 19% in the quarter, reflecting reductions in both fixed and variable expenses following cost actions implemented throughout the year. Net loss from continuing operations improved to $31.8 million from $54.4 million in 4Q25, while Adjusted EBITDA improved to $0.6 million from negative $9.6 million. For FY26, revenues from continuing operations were $238.3 million, down 18%, with approximately half of the decline attributable to the reduction in Seeds and HB4-related activities. Gross profit declined 21% to $82.9 million, with the largest decline in Crop Nutrition, reflecting a lower contribution from the Syngenta agreement, partially offset by improved contribution from microbeaded fertilizers. SG&A expenses declined 24% to $71.2 million, outpacing the reduction in revenues and reflecting the cost actions implemented during the year. Net loss from continuing operations was $54.4 million compared to $49.1 million in FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million. For a full version of Bioceres Crop Solutions’ fiscal fourth quarter 2026 and full year 2026 earnings release, click here. Fiscal Fourth Quarter and Fiscal Year 2026 Earnings Conference Call Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website. To access the call, please use the following information: About Bioceres Crop Solutions Corp. Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. For more information, visit here. Forward-Looking Statements This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, statements regarding the Company’s expected operating performance and cash generation, cost and working-capital initiatives, ability to address its capital structure and liquidity needs, refinancing and liability-management activities, the outcome of pending litigation and disputes, and the future performance of its continuing businesses. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled "Risk Factors" in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law. Unaudited Consolidated Statement of Financial Position(Figures in million of U.S. dollars) View source version on businesswire.com: https://www.businesswire.com/news/home/20260914032481/en/ Contacts Bioceres Crop SolutionsPaula SavantiHead of Investor [email protected]

This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bioceres Crop Solutions Corp (NASDAQ:BIOX) is focusing on operational refocusing and transitioning, which is expected to strengthen the fundamentals of the organization. The company has made progress in reducing operational expenses, which partially offset the decline in total revenues and gross profits. Crop nutrition segment posted a 15% year-over-year revenue growth, driven by microbeaded fertilizer and stronger demand dynamics. Bioceres Crop Solutions Corp (NASDAQ:BIOX) is advancing initiatives aimed at simplifying the organization and improving operational efficiency. The company is reinforcing governance and internal processes, conducting a strategic review of operations to optimize capital allocation. Bioceres Crop Solutions Corp (NASDAQ:BIOX) reported a net loss of $10 million, primarily due to lower gross profit and increased financial expenses. Total revenue for the quarter declined by 23% compared to the same period last year, reflecting softer market conditions and ongoing portfolio transition effects. The company is facing ongoing litigation related to alleged defaults under note purchase agreements, which adds uncertainty to its financial position. Gross profit for the quarter declined by 30% year-over-year, with a broad-based decline across all segments. Adjusted EBITDA for the quarter was negative $0.6 million, compared to positive $9.1 million in the prior-year quarter, impacted by non-recurrent items and lower gross profit. Warning! GuruFocus has detected 8 Warning Signs with BIOX. Is BIOX fairly valued? Test your thesis with our free DCF calculator. Q: What measures are being taken to improve collections and reduce receivables? A: Ezequiel Simmermajer, CFO, explained that the company is offering incentives to customers to advance receivables and is also encouraging new sales with shorter payment terms that are more common in the industry. Q: Can you provide the operating cash flow for the quarter and year-to-date? A: Federico Trucco, CEO, mentioned that they do not have the exact numbers at the moment but will provide that information during the analyst session. Q: How is the company addressing the ongoing litigation related to the ProFarm Group? A: Jose Roque, General Counsel, stated that the company is actively defending against the noteholders' allegations and pursuing counterclaims. They believe the foreclosure was conducted unreasonably and are challenging the process in court. Q: What was the impact of the ProFarm foreclosure on the company's financials? A: Ezequiel Simmermajer, CFO, detailed that the foreclosure resulted in a non-cash impairment and loss of approximately $179 million, primarily affecting intangible assets, goodwill, and other financial metrics. Q: How did the different segments perform in terms of revenue and gross profit? A: Ezequiel Simmermajer, CFO, reported a 23% decline in total revenue, with crop protection down 18%, seeds and integrated products down 71%, and crop nutrition up 15%. Gross profit declined 30% year-over-year, with varying impacts across segments. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. The quarter reflects a period of transition and operational refocusing, historically the company's weakest period due to Southern Hemisphere seasonality. Performance was impacted by the absence of non-recurring IP rights and commercial arrangement profits, which typically offset baseline operating losses in previous years. Crop Protection revenues declined due to softened demand and competitive pressure in adjuvants and third-party products, alongside inventory adjustments in the nutrition channel. The Seeds and Integrated Products segment saw a 71% revenue drop as part of a deliberate shift toward an asset-light, lower working capital-intense model by phasing out downstream grain sales. Crop Nutrition was the sole growth segment, driven by micro fertilizers and global supply uncertainties stemming from geopolitical tensions. Management is prioritizing organizational streamlining and cost control, which resulted in a meaningful reduction in operating expenses during the quarter. The company is conducting a strategic review of continuing operations to ensure resources are aligned with areas of greatest long-term value creation. Management is advancing a reprofiling process for Rizobacter debt in Argentina, including voluntary maturity extensions and coordination with banking partners. Future financial flexibility depends on the outcome of ongoing litigation regarding the purported acceleration of secured notes and the Pro Farm foreclosure. Strategic focus remains on stabilizing the platform through tighter capital allocation, working capital discipline, and improved cash generation. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. The Pro Farm business was reclassified as discontinued operations following a foreclosure auction where a noteholder entity acquired assets via a $15 million credit bid. A non-cash impairment loss of approximately $179 million was recognized in the second quarter, primarily impacting intangible assets and goodwill. Substantially all debt related to the noteholder dispute is now classified as short-term following an acceleration notice, which the company is vigorously contesting. The company asserts that the foreclosure was conducted in a 'commercially unreasonable manner' and has filed counterclaims against the plaintiffs. Management is incentivizing customers to advance payments on receivables to prioritize liquidity. New sales are being structured with shorter payment terms more aligned with industry standards to reduce working capital intensity.

Total revenues in 3Q26 were $39.4 million 3Q26 net loss was $10.0 million and Adjusted EBITDA1 was $(0.6) million ROSARIO, Argentina, May 11, 2026--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2026. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Presentation of Results In January 2026, the Company’s Pro Farm Group (PFG) business was subject to a foreclosure auction and has been classified as discontinued operations. Accordingly, unless otherwise indicated, the financial results discussed below reflect the Company’s continuing operations for all periods presented, and prior-year amounts have been recast to exclude the PFG business. Financial & Business Highlights Total revenues were $39.4 million in 3Q26, a 23% year-over-year decline, reflecting softer demand and competitive pressures in Crop Protection, together with the ongoing transition in Seeds. Crop Nutrition revenues increased 15% during the quarter. Gross profit was $12.7 million, with gross margin of 32%, reflecting lower revenues and product mix effects across segments. Crop Nutrition results were impacted by a non-recurring obsolescence adjustment in inoculants related to inventory normalization efforts. SG&A expenses declined 16% year over year, reflecting continued execution of organizational streamlining and cost management initiatives across the continuing operations. Net loss was $10.0 million and Adjusted EBITDA1 was $(0.6) million, primarily reflecting lower gross profit and the absence of prior-year non-cash income associated with the reorganization in Seeds. Following the Pro Farm foreclosure auction earlier this year, and the related noteholder dispute, the Company continued advancing liability management initiatives across its operating subsidiaries, including debt reprofiling efforts and a voluntary bond maturity extension process in Argentina. Management Review Mr. Federico Trucco, Bioceres’ Chief Executive Officer, commented: "This quarter reflects a period of transition and operational refocusing for the Company. While market conditions in several areas of our business remain challenging, and the effects of the transition in Seeds continue to weigh on reported results, we are increasingly focused on strengthening the fundamentals of the organization and prioritizing disciplined execution across the platform. "During the quarter, we continued advancing initiatives aimed at simplifying the organization, improving operational efficiency, strengthening working capital management and improving cash generation and liability management across key operating subsidiaries. In parallel, we are reinforcing governance and internal processes and conducting a strategic review of our continuing operations — including initiatives focused on organizational streamlining and capital allocation optimization — to ensure that capital, management attention, and resources remain aligned with the areas where we believe we can create the greatest long-term value. "We recognize the significance of the events surrounding Pro Farm and the uncertainty generated by the ongoing litigation process. While we continue to pursue the appropriate legal course and evaluate constructive alternatives where possible, our priority remains clear: stabilizing the business, preserving the value of our core operations, and positioning the Company for a more resilient and sustainable future." 3Q26 Summary: Revenue performance in the third quarter reflects mixed demand dynamics across segments, particularly in Crop Protection, together with the ongoing transition in Seeds toward a more asset-light model. While these factors weighed on reported revenues, Crop Nutrition continued to grow, driven by microbeaded fertilizers. Gross profit and margins declined year over year, reflecting lower revenues, product mix effects, and the impact of a non-recurring obsolescence adjustment in inoculants, associated with inventory normalization efforts during the period. At the same time, the Company continued to execute on cost management and working capital initiatives, resulting in meaningful reductions in operating expenses and improvements in cash conversion dynamics during the quarter. Profitability metrics were additionally impacted by the absence of prior year non-cash income associated with changes in contractual obligations and intellectual property arrangements as part of the reorganization in Seeds, which affected year-over-year comparability. For a full version of Bioceres’ third quarter 2026 earnings release, click here Fiscal Third Quarter 2026 Earnings Conference Call Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website. To access the call, please use the following information: About Bioceres Crop Solutions Corp. Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. For more information, visit here. Forward-Looking Statements This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled "Risk Factors" in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511356435/en/ Contacts Bioceres Crop Solutions Paula Savanti Head of Investor Relations [email protected]